Nex Genix Pharmaceuticals
Pharmaceuticals, 849 Mitten Rd Ste 104, Burlingame, California, 94010, United States, 1-10 Employees
Phone Number: +16*********
Who is NEXGENIX PHARMACEUTICALS
NexGenix is a privately-held drug discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system such as glioblasto...
Read More
-
Headquarters: 849 Mitten Rd Ste 104, Burlingame, California, 94010, United States
-
Employees: 1-10
-
Revenue: $5 Million to $10 Million
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from NEXGENIX PHARMACEUTICALS
NexGenix Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NexGenix Pharmaceuticals
Answer: NexGenix Pharmaceuticals's headquarters are located at 849 Mitten Rd Ste 104, Burlingame, California, 94010, United States
Answer: NexGenix Pharmaceuticals's phone number is +16*********
Answer: NexGenix Pharmaceuticals's official website is https://nexgenixpharm.com
Answer: NexGenix Pharmaceuticals's revenue is $5 Million to $10 Million
Answer: NexGenix Pharmaceuticals's SIC: 2834
Answer: NexGenix Pharmaceuticals's NAICS: 621111
Answer: NexGenix Pharmaceuticals has 1-10 employees
Answer: NexGenix Pharmaceuticals is in Pharmaceuticals
Answer: NexGenix Pharmaceuticals contact info: Phone number: +16********* Website: https://nexgenixpharm.com
Answer: NexGenix is a privately-held drug discovery and development company focused on the "next generation" of targeted therapies for cancer and diseases of the nervous system such as glioblastoma, neurodegenerative diseases, neurofibromatosis, and autism-spectrum disorders. The Company has acquired, through in-licensing and research collaboration, a robust structural chemistry platform in resorcylic macrolides, highly potent inhibitors of the chaperone, heat shock protein 90 (Hsp90). The concept that numerous diseases, including cancer, neurofibromatosis, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and Parkinson's disease involve misregulation of protein homeostasis presents a unique opportunity for drug development for these varied disorders. NexGenix's novel Hsp90 inhibitors, based on the highly potent compound radicicol, exhibit the potential to be best in class drugs. NexGenix has world-class scientific advisors and collaborators in the areas of protein folding, kinase signaling and oncogenesis, and neurodegenerative diseases. The company additionally has a growing portfolio of intellectual property covering its key efforts.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month